Soft tissue sarcoma is a rare type of cancer. Currently, one of the most common subtypes of sarcoma are leiomyosarcomas (LMS), which represent 16% of this pathology, and more frequently affect middle-aged adults and older, predominating among women.
The orphan drug designation is a status granted by the EMA to medicines intended to treat rare or uncommon diseases, which affect less than 5 people per 10,000 inhabitants in the
Orphan drug designation offers several benefits to drug manufacturers, including exemption from some EMA fees, scientific and regulatory advice during drug development, and the possibility of receiving tax benefits and market exclusivity for a period of 10 years in the
Contact:
Tel: +34 91 846 6000
Fax: 91 846 6001
Email: pharmamar@pharmamar.com
(C) 2023 Electronic News Publishing, source